Immunization with SARS Coronavirus Vaccines Leads to Pulmonary Immunopathology on Challenge with the SARS Virus

摘要: Background Severe acute respiratory syndrome (SARS) emerged in China 2002 and spread to other countries before brought under control. Because of a concern for reemergence or deliberate release the SARS coronavirus, vaccine development was initiated. Evaluations an inactivated whole virus ferrets nonhuman primates virus-like-particle mice induced protection against infection but challenged animals exhibited immunopathologic-type lung disease. Design Four candidate vaccines humans with without alum adjuvant were evaluated mouse model SARS, VLP vaccine, given NHP, another rDNA-produced S protein. Balb/c C57BL/6 vaccinated IM on day 0 28 sacrificed serum antibody measurements live 56. On 58, lungs obtained histopathology. Results All neutralizing increasing dosages and/or significantly responses. Significant reductions SARS-CoV two days after challenge seen all prior SARS-CoV. All histopathologic changes including (Balb/C C57BL/6) virus, influenza PBS suggesting occurred all. Histopathology one uniformly Th2-type immunopathology prominent eosinophil infiltration, confirmed special stains. The pathologic control groups lacked prominence. Conclusions These However, any led occurrence hypersensitivity components induced. Caution proceeding application is indicated.